Acute bacterial skin infections and cellulitis

Current Opinion in Infectious Diseases

Volumn 20, Issue 2, 2007, Pages 118-123

  Gabillot Carré, Marion ^a   Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute bacterial skin infection; Cellulitis; Erysipelas; Necrotizing fasciitis; Skin and soft tissue infection

Indexed keywords

ANTIBIOTIC AGENT; BENZATHINE PENICILLIN; CEFAZOLIN; DAPTOMYCIN; IMMUNOGLOBULIN; LEVOFLOXACIN; LINEZOLID; PLACEBO; TIGECYCLINE; VANCOMYCIN;

ABSCESS; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; BACTERIOLOGY; CELLULITIS; CLINICAL TRIAL; ERYSIPELAS; HEALTH CARE COST; HUMAN; HYPOTENSION; INTERTRIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIPLE ORGAN FAILURE; NECROTIZING FASCIITIS; NONHUMAN; PROGNOSIS; REVIEW; RISK FACTOR; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; TOXIC SHOCK SYNDROME;

CELLULITIS; COMMUNITY-ACQUIRED INFECTIONS; ERYSIPELAS; FASCIITIS, NECROTIZING; HUMANS; INTERTRIGO; METHICILLIN RESISTANCE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33847407971     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32805dfb2d     Document Type: Review

References (39)

1. Kaul R, McGeer A, Low DE, et al. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognosis indicators and microbiologic analysis of seventy-seven cases. Am J Med 1997; 103:18-24.
2. Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006; 20:834-839. High incidence (179.6/100 000) in general practice. Only 7% of patients were hospitalized, accounting for 83% of treatment costs.
3. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591-1594.
4. Roujeau JC, Sigugeirsson B, Korting HC, et al. Chronic derematomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 309:301-307.
5. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005; 41:1416-1422.
6. Mokni M, Dupuy A, Denguezli M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006; 212:108-112. Also in Tunisia, leg edema or lymphedema and cutaneous barrier disruption by traumatic wound, excoriated dermatosis or toe-web intertrigo are risk factors for erysipelas of the leg.
7. Liu YM, Chi CY, Ho MW, et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect 2005; 38:430-435.
8. Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal anti-inflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine 2003; 82:225-235.
9. Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis 2005; 75:177-180.
10. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the management of skin and soft tissue infections. Clin Infect Dis 2005; 41:1373-1406.
11. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988; 148:2451-2452.
12. Bernard P, Bedane C, Mounier M, et al. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125:779-782.
13. Zinderman CE, Conner B, Malakooti MA, et al. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10:941-944.
14. Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11:928-930.
15. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-674. Multicenter study in 11 university affiliated emergency departments demonstrating the growing role of CA-MRSA in skin and soft tissue infections, including cellulitis with collection and exudates.
16. Nguyen DM, Mascola L, Brancoft E. Recurring methicillin-resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis 2005; 11:526-532.
17. Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 2004; 39:1446-1453.
18. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976-2984.
19. Hiramatsu K, Okuma K, Ma XX, et al. New trends in Staphylococcus aureus infections: glycopetide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis 2002; 15:407-413.
20. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468-475.
21. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41:5113-5120.
22. Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J 2005; 24:201-206.
23. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-1453.
24. Wong CH, Kurup A, Wang YS, et al. Four cases of necrotizing fasciitis caused by Klebsiella species. Eur J Clin Microbiol Infect Dis 2004; 23:403-407.
25. Grayson ML, Silvers J, Turnidge J. Home intravenous therapy. A safe and effective alternative to inpatient care. Med J Aust 1995; 162:249-253.
26. Corwin P, Toop L, McGeoch G, et al. Randomized controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 2005; 330:129.
27. Donald M, Marlow N, Swinburn E, Wu M. Emergency department management of home intravenous antibiotic therapy for cellulitis. Emerg Med J 2005; 22:715-717.
28. Grayson ML, McDonald M, Gibson K, et al. Once daily IV cephazolin plus oral probenecid is equivalent to once daily IV ceftriaxone plus oral placebo for the treatment ofmoderate to severe cellulitis. Clin Infect Dis 2002; 34:1440-1448.
29. Cox VC, Zed PJ. Once-daily cefazolin and probenecid for skin and soft tissue infections. Ann Pharmacother 2004; 38:458-463.
30. Fridkin SK, Hageman JC, Morrison M, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436-1444.
31. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23:123-127.
32. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994-1000.
33. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25:185-192.
34. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-2266.
35. Matthew JH, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-1674.
36. Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J Eur Acad Dermatol Venereol 2006; 20:818-822. A high level of recurrences in this series points to the need for formal studies of prophylaxis.
37. Darrenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340.
38. Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis 2003; 37:341-343.
39. Chelsom J, Halstensen A, Haga T, Todd J. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111-1115.